Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.

Removing both ovaries treated the woman's excess male hormone symptoms.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Rare adrenal cancers that secrete androgens or estrogens have a poor prognosis and are treated primarily with surgery.

Estrogen alone can lower testosterone in some transfeminine people.

Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

Removing an adrenal tumor can significantly reduce high androgen levels in postmenopausal women.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

GnRH-a or orchiectomy is more effective than anti-androgens for managing hormone levels in transgender women.

GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.

Testosterone patches can modestly improve sexual function in postmenopausal women not on estrogen therapy.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Androgen deprivation therapy might help prevent severe COVID-19, but more research is needed.

Tamoxifen effectively treats gynecomastia without causing impotence.

Antiandrogen therapy is effective and well tolerated for treating women's androgenic disorders like hirsutism, acne, and hair loss.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

Dutasteride injections can help treat hair loss in men and women.

Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.

A six-drug treatment for metastatic breast cancer showed promising results with low side effects, especially in premenopausal women.

Mesotherapy with dutasteride effectively treats hair loss with manageable side effects.

Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.